Wyss InstituteSepsis – Wyss Institute https://wyss.stage.a17.io Wyss Institute at Harvard Thu, 30 Jul 2026 21:38:59 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.6 Wyss Institute team selected by DARPA-SHIELD program to develop first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic https://wyss.stage.a17.io/news/wyss-institute-team-selected-by-darpa-shield-program-to-develop-first-of-its-kind-biologically-engineered-broad-spectrum-antimicrobial-therapeutic/ Mon, 16 Sep 2024 13:25:50 +0000 https://wyss.harvard.edu/?p=40989 Easily deployable and fast-acting approach combines pathogen-binding and immune-activating technologies to assemble a living pathogen-targeting machinery in traumatized individuals By Benjamin Boettner (BOSTON) — Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University received a contract for up to $12M from the Defense Advanced Research Projects Agency (DARPA)’s new SHIELD program. The SHIELD (Synthetic Hemo-technologies to Locate and Disinfect) program aims to develop a prophylactic treatment that can be broadly administered to…

Source

]]> https://wyss.stage.a17.io/news/wyss-institute-team-selected-by-darpa-shield-program-to-develop-first-of-its-kind-biologically-engineered-broad-spectrum-antimicrobial-therapeutic/ This collaborative research team at the Wyss Institute led by Samir Mitragotri (on the far right) and Michael Super (left of Mitragotri) won a DARPA-SHIELD contract to develop a first-of-its-kind biologically engineered broad-spectrum antimicrobial therapeutic that can be broadly administered to trauma victims without immediate access to health care facilities. Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2024/09/12130928/SM_Darpa-Shield-Team-Photo-02154-copy.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=0b89c99b44febedf253816eadce2e581"/> Reimagining Protein Engineering Inspired by His Father: Mike Super https://wyss.stage.a17.io/media-post/reimagining-protein-engineering-inspired-by-his-father-mike-super/ Thu, 12 Jan 2023 16:33:16 +0000 https://wyss.harvard.edu/?post_type=media_post&p=35299 Mike Super is a Lead Staff Scientist using protein engineering to design therapeutic and diagnostic devices to treat cancer, and infectious and immunological diseases. He also leads the Biostasis team at the Wyss. In this video, he shares his personal and professional journey that began in the deserts of Namibia shadowing his father, one of the few pediatricians in the area. We learn how his…

Source

]]> https://wyss.stage.a17.io/media-post/reimagining-protein-engineering-inspired-by-his-father-mike-super/ https://wyss-stage.imgix.net/app/uploads/2023/01/11142924/THUMBNAIL_Reimagining-Protein-Engineering-Inspired-By-His-Father_Mike-Super_No-Text.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=c90ccb325379dfd7d22799c7dbbda278"/> Accelerating pathogen identification in infants and children with bloodstream infections https://wyss.stage.a17.io/news/accelerating-pathogen-identification-in-infants-and-children-with-bloodstream-infections/ Fri, 02 Dec 2022 20:44:23 +0000 https://wyss.harvard.edu/?p=34762 Fast and highly efficient engineered pathogen capture method shortcuts accurate detection of pathogens in small blood samples, which could help save lives By Benjamin Boettner / Wyss Institute Communications (LONDON) — A collaborative team led by researchers from Great Ormond Street Institute of Child Health (GOSH), London and including researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and BOA Biomedical in Cambridge has re-engineered the process of microbial pathogen identification in blood samples…

Source

]]> https://wyss.stage.a17.io/news/accelerating-pathogen-identification-in-infants-and-children-with-bloodstream-infections/ A research collaboration re-engineered and shortcut the process of microbial pathogen identification in blood samples from pediatric sepsis patients using the Wyss Institute’s FcMBL broad-spectrum pathogen capture technology, which could significantly improve clinical outcomes. Credit: Shutterstock https://wyss-stage.imgix.net/app/uploads/2022/12/02131727/shutterstock_1099258427.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=f4748fe9fff000d418e5ca97b4c291d9"/> eRapid: developing a multiplexed electrochemical diagnostic platform from the ground up https://wyss.stage.a17.io/news/erapid-developing-a-multiplexed-electrochemical-diagnostic-platform-from-the-ground-up/ Thu, 09 Sep 2021 17:24:34 +0000 https://wyss.harvard.edu/?p=29901 Wyss researchers describe their journey in developing the eRapid technology for fast and inexpensive diagnostic testing of multiple biomarkers at the point-of-care By Benjamin Boettner (BOSTON) – In an article published in the prestigious Accounts in Chemical Research, Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., and his sensor team led by Senior Staff Scientist Pawan Jolly, Ph.D. in the Wyss Institute’s Bioinspired Therapeutics & Diagnostics Platform, describe the development and evolution of their eRapid affinity-based electrochemical…

Source

]]> https://wyss.stage.a17.io/news/erapid-developing-a-multiplexed-electrochemical-diagnostic-platform-from-the-ground-up/ Wyss researchers developed a novel antifouling nanocomposite coating to cover the electrodes on eRapid chips, which now use graphene-oxide nanoflakes to conduct electricity and has binding reagents for different biomarkers embedded into it. The coating enables the transfer of ions through nanopores to the electrode surface, while repelling biofouling agents that otherwise would render the electrode surface useless in a short time. Coupled with additional surface chemistry this enables the conversion of a biomarker binding event to an electrical signal that correlates in strength with the levels of target biomarkers detected. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2021/09/08155728/eRapid_282A0391.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=308463d4f1047cbc40bf38946967d949"/> Biomaterial vaccines ward off broad range of bacterial infections and septic shock https://wyss.stage.a17.io/news/biomaterial-vaccines-ward-off-broad-range-of-bacterial-infections-and-septic-shock/ Thu, 08 Jul 2021 15:00:29 +0000 https://wyss.harvard.edu/?p=29281 A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases By Benjamin Boettner (BOSTON) — Current clinical interventions for infectious diseases are facing increasing challenges due to the ever-rising number of drug-resistant microbial infections, epidemic outbreaks of pathogenic bacteria, and the continued possibility of new biothreats that might emerge in the future. Effective vaccines could act as a bulwark to prevent many bacterial infections and…

Source

]]> https://wyss.stage.a17.io/news/biomaterial-vaccines-ward-off-broad-range-of-bacterial-infections-and-septic-shock/ Effective vaccines could act as a bulwark to prevent many bacterial infections and some of their most severe consequences, including sepsis. “Each year, at least 1.7 million adults in America develop sepsis. Nearly 270,000 Americans die as a result of sepsis [and] 1 in 3 patients who dies in a hospital has sepsis” (Centers of Disease Control and Prevention). Credit: Shutterstock/Kateryna Kon https://wyss-stage.imgix.net/app/uploads/2021/07/07140616/shutterstock_1232409307.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=f7d1734993a832edf1a15e2830f9d430"/> Detecting multiple sepsis biomarkers from whole blood – made fast, accurate, and cheap https://wyss.stage.a17.io/news/detecting-multiple-sepsis-biomarkers-from-whole-blood-made-fast-accurate-and-cheap/ Fri, 12 Feb 2021 16:58:57 +0000 https://wyss.harvard.edu/?p=27418 The Wyss Institute’s eRapid electrochemical sensor technology now enables sensitive, specific, and multiplexed detection of blood biomarkers at low cost with potential for many clinical applications By Benjamin Boettner (BOSTON) — Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment. In patients who suffer infection by an unknown pathogen that then progresses to overt sepsis, every additional hour that an effective antibiotic cannot be administered…

Source

]]> https://wyss.stage.a17.io/news/detecting-multiple-sepsis-biomarkers-from-whole-blood-made-fast-accurate-and-cheap/ Wyss Institute researchers have developed eRapid technology as an affinity-based, low-cost electrochemical diagnostic sensor platform for the multiplexed detection of clinically relevant sepsis biomarkers in whole blood. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2021/02/10163737/Don_pawan_AFM-press-release.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=9af68535caeadebcf6c6e4771b692c86"/> Rapid Metabolite-Sensing System for Blood Lactate https://wyss.stage.a17.io/technology/rapid-metabolite-sensing-system-for-blood-lactate/ Wed, 02 Sep 2020 20:58:10 +0000 https://wyss.harvard.edu/?post_type=technology&p=25831 In emergency medicine, blood lactate levels are a reliable real-time indicator of the severity and mortality risk of conditions that occur as a result of poor blood circulation and oxygen supply to organs and tissues (hypoperfusion), such as in patients with sepsis, cardiac arrest, stroke, major trauma, cystic fibrosis and other conditions. Lactate levels also provide an early measure for the…

Source

]]> https://wyss.stage.a17.io/technology/rapid-metabolite-sensing-system-for-blood-lactate/ This scanning electron cryomicroscopic (CryoSEM) image shows the size and morphology of lactate-sensing liposomes produced by the approach. Credit: Wyss Institute at Harvard University. https://wyss-stage.imgix.net/app/uploads/2020/09/02103144/P2_CryoSEM_22_purple.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=3e8222097d899a74cb300003ca721370"/> Overhauling diagnostics for better patient care https://wyss.stage.a17.io/news/overhauling-diagnostics-for-better-patient-care/ Tue, 17 Sep 2019 15:00:54 +0000 https://wyss.harvard.edu/?p=21982 10th International Wyss Institute Symposium will focus on novel ways to identify disease By Benjamin Boettner and Lindsay Brownell For all the progress that has been made over the last century in treating previously fatal diseases – pneumonia, tetanus, and hepatitis C, to name a few – modern science still lags behind in improving the speed, accuracy, ease, and sometimes even the mere possibility of diagnosing many diseases. This is especially problematic in conditions like cancer…

Source

]]> https://wyss.stage.a17.io/news/overhauling-diagnostics-for-better-patient-care/ FISSEQ allows molecules of RNA to be identified within 3D tissue samples, giving scientists valuable information about where in the body certain genes are active during healthy and diseased states. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2019/09/16142154/FISSEQ-b1.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=6d4882090c317dec8c7997bad31f851d"/> FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy https://wyss.stage.a17.io/technology/fcmbl-broad-spectrum-pathogen-capture-for-infectious-diseases/ Wed, 11 Sep 2019 00:35:45 +0000 https://wyss.prod.a17.io/technology/capture-and-concentration-of-microbial-pathogens-fcmbl/ BOA Biomedical is developing the Wyss Institute's FcMBL pathogen-capture technology into products that quickly remove pathogens from the body and enable their rapid identification, giving critically ill patients a higher chance of survival. Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis is very common – one out of every three…

Source

]]> https://wyss.stage.a17.io/technology/fcmbl-broad-spectrum-pathogen-capture-for-infectious-diseases/ https://wyss-stage.imgix.net/app/uploads/2016/08/08120525/Staph-Beads-Gold.light_.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=9aeaddc3a36a160164da784a440804b2"/> Wyss Institute and Miraki Innovation Unveil BOA Biomedical to Reduce Sepsis Deaths https://wyss.stage.a17.io/news/wyss-institute-and-miraki-innovation-unveil-boa-biomedical-to-reduce-sepsis-deaths/ Tue, 10 Sep 2019 18:33:49 +0000 https://wyss.harvard.edu/?p=21903 New venture’s platform technology can rapidly diagnose and treat a broad range of antibiotic-resistant infectious diseases (CAMBRIDGE, Mass.) — The Wyss Institute for Biologically Inspired Engineering at Harvard University and Miraki Innovation have unveiled BOA Biomedical Inc., a company that aims to solve the global healthcare demand for a device that rapidly diagnoses and treats infectious diseases, focusing specifically on sepsis and antibiotic-resistant infections. BOA is a portfolio company founded by Miraki…

Source

]]> https://wyss.stage.a17.io/news/wyss-institute-and-miraki-innovation-unveil-boa-biomedical-to-reduce-sepsis-deaths/ The technology that BOA has licensed from the Wyss Institute physically removes bacteria and other pathogens from the blood, which helps to avert sepsis, allows for faster identification of the infectious agent, and can help combat antibiotic resistance. Credit: Wyss Institute at Harvard University https://wyss-stage.imgix.net/app/uploads/2019/09/10112002/Staph-015-Color.jpg?auto=format%2Ccompress&crop=faces%2Centropy&fit=crop&h=400&q=50&w=300&s=7c4575579b3d7b93f2d432b485fd5930"/>